Look with all due respect if you took the time to read my "so called" long winded reply you may come to the understanding the graphs, charts or whatever it is you are presenting is irrelevant in Vaxinia's situation. The reason posts are often as you suggest "long winded" is they contain definitions, details and statistics relevant to the topic at hand. I could go into great detail as to which BP drugs have obtained approval in a third of the time suggested by you, or which of the 74% of drugs approved through expedited pathways referred to in my post were granted FDA Approval in less than half the time indicated in your slides, but I would be in danger of become long winded, in stating the facts.
It is my understanding YF and those supervising the current trial are looking to realise the markers necessary to reach an intermediate clinical endpoint if not a surrogate endpoint by the end of this year, at the latest in the first half of 2025. There current Trial has nothing to do with traditional clinical trial time frames due to the existing relationship YF and Imugene personnel have with the FDA, coupled with virus's existing results, subsequent fast track designation and priority review status afforded to it. Not to forget the pressure the FDA is under from Congress to find and approve low cost efficacious drugs within the cancer spectrum. FYI I am acutely aware of the time taken to realise regulatory approvals within traditional clinical trial guidelines. I started investing significant amounts of investor funds into the sector in 1992, and at some stages my advisory firm had 10's upon 10's of millions of dollars and the rest invested in the biotech sector for extended periods during the boom and bust decades of the 90/s and early 2000's, in solo stocks, managed funds or wrap accounts.
And btw please don't bring up Chimeric, Radiopharm or for that matter Arovella slides again in my presence. I feel as if every time I see them Imugene are going to be asked to either lend them some drugs for a not for profit combination, pay them a fee for some drug they've located or stand in comparison as examples of like minded Aussie biotechs, when in essence they are worlds apart.
Apologies for sounding disgruntled, but I guess I am. You write a post and people read a tenth of it, then digest the segments they choose to inhale and misconstrue them completely. But for the sake of expediency and conciliation with a view to closing this argument out, I shall agree with you. Four years would be really, really fast.
DYOR
Expand
(20min delay)